Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

Share this content:
Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation.
Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation.

Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation, and women with estrogen receptor-negative breast cancer and a BRCA1 mutation should undergo the procedure shortly after diagnosis, according to research published in JAMA Oncology.

Researchers followed 676 women who had early-stage breast cancers and were carriers of BRCA1 or BRCA2 mutations.

The women had received treatment for breast cancer, including mastectomy and lumpectomy. Roughly half had undergone an oophorectomy.

Overall, 77.4 percent of women survived over the 20-year follow-up from time of diagnosis, the findings showed. In women who underwent oophorectomy, the adjusted hazard ratio for breast cancer-specific mortality was 0.38 (95 percent confidence [CI], 0.19 to 0.77; P = 0.007) for BRCA1 carriers and 0.57 (95 percent CI, 0.23 to 1.43; P = 0.23) for BRCA2 carriers.

RELATED: After Breast Cancer, Many Women Express Desire for Genetic Testing

For women with estrogen receptor-positive breast cancer, the hazard ratio for breast cancer-specific mortality was 0.76 (95 percent CI, 0.32 to 1.78; P = 0.53), and for women with estrogen receptor-negative breast cancer, the hazard ratio was 0.07 (95 percent CI, 0.01 to 0.51; P = 0.009).

On average, oophorectomy was done six years after the breast cancer diagnosis, but earlier oophorectomy conferred a greater reduction in breast cancer death risk.

The protective effect of oophorectomy was especially strong if women had estrogen receptor-negative breast cancer after age 50.

Reference

  1. Metcalfe, Kelly, PhD, et al. "Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers." JAMA Oncology. doi:10.1001/jamaoncol.2015.0658. [epub ahead of print]. April 23, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs